Before Indian drugmaker Aurobindo can complete its acquisition of Pennsylvania generics specialist Lannet, it will have to divest four drugs from the proposed $250 million buyout to resolve anticompetitive concerns, the Federal Trade Commission said. “Aurobindo’s acquisition of Lannett would combine two of a limited number of competitors in the markets for four different generic pharmaceutical products that provide critical relief for patients,” the FTC wrote of its proposed consent order. The U.S. regulator has specified that Aurobindo must sell the products to New Jersey generics maker Quagen Pharmaceuticals.
Read the full article: FTC Orders Aurobindo to Divest 4 Drugs to Complete $250M Lannett Acquisition //
Source: https://www.fiercepharma.com/pharma/ftc-advises-aurobindo-divest-4-drugs-complete-250m-acquisition-lannett